Andrographis
Best-in-class: Andrographis
An immune herb with strong evidence for shortening colds and respiratory infections — sometimes called 'Indian echinacea.'
Andrographis quick facts
| Suggested dose | As directed at first symptoms (standardized andrographolides). |
| How often | Acute only - at the first symptom, short courses |
| Who it's for | Cold/flu and respiratory-infection support. |
Meta-analysis supports symptom reduction in upper-respiratory infection, and it is one of the better-evidenced botanicals here. It is intensely bitter, which limits compliance in unencapsulated form. Real cautions: it may be abortifacient, has antiplatelet activity, and there are rare reports of anaphylaxis and liver injury. Not one for continuous long-term use.
How Andrographis actually works
Andrographolide has anti-inflammatory activity through NF-kB inhibition, plus immunostimulant and antiviral effects in vitro. It is one of the more pharmacologically active herbs in this category rather than a gentle traditional remedy.
Where to get Andrographis
Find Andrographis on iHerb →The evidence for Andrographis
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses support reduced severity and duration of upper-respiratory infections.
- Immune-modulating and anti-inflammatory activity.
📊 Correlative data
- Traditional cold/fever use aligns with the respiratory-infection trials.
🧪 Theoretical / extrapolated benefits
- Andrographolide inhibits NF-κB and has documented antiviral activity in vitro against several respiratory viruses. The prediction is a shortened and blunted upper respiratory infection rather than prevention of one — which matches where the trial signal actually sits.
- Predicted downside worth naming: the same immune modulation is theoretically the wrong direction in autoimmune disease, and there are case reports of anaphylaxis. Not a supplement to take continuously.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Andrographis actually does
Andrographolide is a labdane diterpenoid carrying an alpha-alkylidene gamma-butyrolactone — an electron-poor double bond next to a carbonyl. That arrangement is a Michael acceptor, which means it does not bind a target, it reacts with one. And the reaction has been pinned down: andrographolide forms a covalent adduct with the reduced cysteine 62 of NF-kappaB p50, the residue that makes contact with DNA, abolishing p50 binding Xia 2004.
Why that is a different mechanism from everything else on this shelf. Most anti-inflammatory botanicals are described as interfering with NF-kappaB activation — keeping it bound to IkappaB, stopping it entering the nucleus. Andrographolide does not do that. IkappaB-alpha degradation was unaffected; the transcription factor is released as normal and then cannot read the DNA when it arrives Xia 2004. The downstream consequences measured were reduced E-selectin expression on endothelium and prevention of allergic lung inflammation in vivo.
Three things follow from the chemistry, and all three are checkable predictions rather than adjectives. First, a covalent modifier has no occupancy to titrate: the effect is set by how much reactive lactone reaches the cysteine, not by a steady-state concentration. Second, a Michael acceptor is reactive toward any accessible thiol, glutathione included, which is a competing sink that nobody has measured in a person taking this. Third — and this is the useful one — blocking an already activated transcription factor predicts a blunted illness rather than a prevented one, because there is nothing to block until the infection has started the signaling.
That predicted shape is exactly the shape of the clinical evidence, which is a rare thing on this shelf and is the reason this page treats andrographis more seriously than its neighbors.
Cell, rodent, human — and where it stops
In cells and in animals. Covalent modification of p50 Cys62, loss of DNA binding, reduced E-selectin in endothelial cells, and prevention of allergic lung inflammation in vivo Xia 2004.
In people, and here the evidence is unusually deep. An early systematic review covered 7 trials in 896 participants and found the herb superior to placebo for uncomplicated upper respiratory infection with mild adverse events Coon 2004. A later systematic review and meta-analysis pooled 33 randomized trials across 7,175 patients and reported improvement against placebo for cough, standardized mean difference −0.39 (95% CI −0.67 to −0.10), and for sore throat, −1.13 (95% CI −1.37 to −0.89) Hu 2017.
So what is the obstacle, when the human data is this large? It is the dose, and it is the one thing a buyer cannot resolve. The trials tested extracts standardized to a stated andrographolide content. This site's own dose field for andrographis says only “as directed at first symptoms (standardized andrographolides)” and names no number at all. A reader holding a capsule therefore has no way to tell whether they are taking a trial dose, a third of one, or three.
The second obstacle is timing, and it is structural rather than statistical. Every positive trial gave the herb to people who were already ill, at or near symptom onset Hu 2017. Nothing in that literature supports taking it continuously through a season, and the mechanism argues against it: with no activated p50 to modify, a covalent inhibitor of DNA binding has nothing to do Xia 2004.
The third is what was measured. These are symptom scales, self-reported, in trials of varying quality; they are not culture-confirmed illness, days off work or transmission. A standardized mean difference of −1.13 for sore throat Hu 2017 is a large effect for a herb and is worth treating with the scepticism any large effect on a subjective scale deserves.
Andrographis — which form, and does it matter
“Total andrographolides” is not andrographolide. The plant contains neoandrographolide and 14-deoxyandrographolide alongside andrographolide itself, and a label standardized to total diterpenoids is quoting a mixture. The Cys62 chemistry has been demonstrated for andrographolide Xia 2004; the others are different molecules whose lactone chemistry differs, and substituting them for the studied one is a silent step.
Whole herb powder against standardized extract. Andrographolide content in the raw plant varies with part, season and source, so an unstandardized herb capsule is an unknown dose of the active by construction. The trials in the meta-analyses used standardized preparations Hu 2017, commonly proprietary ones and commonly fixed combinations with other herbs — which means a single-herb capsule is not automatically the thing that was studied either.
A practical tell, offered as an inference and not as an assay. Andrographolide is the bitter principle; the plant's common names in several languages translate as “king of bitters”. A capsule that tastes of nothing when opened is either well coated or poorly loaded, and bitterness is the one property of this herb that correlates with its active by chemistry rather than by claim.
What would have to be true, and how you would know it was not
1. The prediction that argues against buying a bottle for the season. Because the mechanism requires activated NF-kappaB to act on Xia 2004, predict that taking it daily while well produces no measurable benefit — no reduction in the number of infections across a winter. If somebody finds that daily use prevents illness, that is not this mechanism and something else needs explaining.
2. No resting marker should move. Predict hs-CRP flat after 4 weeks of daily dosing in a well person, for the same reason. A herb that lowers CRP in someone with no inflammation would be doing something the covalent-adduct model does not describe.
3. Severity should respond more than duration, and the meta-analysis is consistent with that. Blocking p50 from reaching its promoters should blunt the cytokine-driven symptoms of an infection more than it shortens viral clearance. The pooled effect on sore throat, −1.13, was substantially larger than the effect on cough, −0.39 Hu 2017 — sore throat being the more directly inflammatory of the two. That is a prediction the existing data already half-tests, and a properly powered trial reporting both severity area-under-curve and time-to-resolution would finish it.
4. On and off, with no lag. A covalent modifier acts on the protein present now, and NF-kappaB p50 turns over. Predict the effect appears within 24 to 48 hours of starting during an illness and is gone within days of stopping — no loading period, no residual priming.
What nobody has tested yet
Nobody has ever looked for target engagement in a human. The mechanism is a covalent adduct on a named cysteine of a named protein Xia 2004, which makes it detectable by mass spectrometry on peripheral blood mononuclear cells. Draw blood, isolate PBMCs, look for modified p50. No trial has done it. For a herb with 33 randomized trials behind it Hu 2017, the absence of a single target engagement measurement is remarkable.
Andrographolide alone against whole extract has not been compared clinically. Every argument that the isolated compound explains the herb, or that the herb outperforms the compound, is currently a preference.
Nobody has measured glutathione. A reactive lactone taken daily is a thiol sink in principle; whether whole-blood or erythrocyte glutathione falls at clinical doses has not been reported, and it is a standard assay.
And the autoimmune caution has never been tested. The concern is entirely mechanistic. No trial has enrolled participants with an autoimmune disease and reported what happened, in either direction, which means the warning on every bottle is a hypothesis wearing the clothes of a finding.
Andrographis — its own safety story, not its category's
The adverse event rate is actually known, which is unusual here. A systematic review and meta-analysis of safety reported non-serious adverse events at 102.6 per 1,000 patients in randomized trials and serious adverse events at 0.02 per 1,000, with gastrointestinal and skin disorders the commonest Worakunphanich 2021. About one person in ten gets something unpleasant, almost always minor. That is a far more useful sentence than “generally well tolerated”.
The anaphylaxis question, answered as far as it has been answered. Hypersensitivity reports exist in pharmacovigilance. When the question was put to an experiment, in guinea pigs and RBL-2H3 mast cells, the extract behaved as non-anaphylactic while andrographolide itself produced mild allergic mediator release Richard 2017. That is information rather than reassurance: an animal model did not reproduce the signal, and animal models of anaphylaxis are not the same as people.
Bleeding risk is asserted and unmeasured. Antiplatelet activity is widely listed for this herb, and there is no human interaction study with warfarin, apixaban, rivaroxaban, clopidogrel or aspirin. Since the claimed mechanism is pharmacodynamic rather than metabolic, it would not show as a changed drug level — it would show as bruising or a raised INR — so the practical advice is to check rather than to assume in either direction.
Pregnancy: avoid. Animal data show antifertility and abortifacient effects, which is a stronger reason than absence of data.
Who should not take it, and the reason is the chemistry. Continuous users. This is a covalent modifier of a transcription factor; the trials are short courses in acute illness Coon 2004 Hu 2017, and no study has run daily andrographolide for a year and looked for anything. An open-ended habit with a reactive electrophile is the one use case this evidence base specifically does not cover.
Sources read for this page
- Xia YF, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. Journal of Immunology 2004 · PMID 15356172
- Hu XY, et al. Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis. PLoS One 2017 · PMID 28783743
- Coon JT, Ernst E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Medica 2004 · PMID 15095142
- Worakunphanich W, et al. Safety of Andrographis paniculata: A systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 2021 · PMID 33372366
- Richard EJ, Murugan S, et al. Is Andrographis paniculata extract and andrographolide anaphylactic?. Toxicology Reports 2017 · PMID 28959670
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Severity by day, and the date it ends. Score the three symptoms you actually have — sore throat, cough, blocked nose — from 0 to 3 each morning, and note the day the total reaches zero. The trials behind this measured exactly that shape: a shorter, flatter illness, not a prevented one.
- How long before it means anything: One illness, started within a day of the first symptom, repeated across several before you decide. It is not a preventive and taking it continuously is neither what was studied nor wise — the same immune modulation runs the wrong way in autoimmune disease, and anaphylaxis has been reported.
- What will fool you: The fact that you started on the worst day. Symptom scores fall from a peak by themselves, so anything begun at a peak looks effective. The second trap is that colds are a grab bag of different viruses of different lengths, so a two-day illness and a nine-day illness are not evidence about a herb. If you are getting several a season, the useful question is why, and that is a doctor's question.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Andrographis — safety & side effects
- GI upset, headache, fatigue and a very bitter taste that many people cannot tolerate.
- Antiplatelet activity and blood-pressure lowering — Additive bleeding risk with anticoagulants and antiplatelets — warfarin, apixaban, rivaroxaban, clopidogrel, and aspirin at any dose. The interaction is pharmacodynamic rather than metabolic, so it does not show up as a changed drug level; it shows up as bruising, nosebleeds or a raised INR.
- Avoid in pregnancy: animal data show antifertility and abortifacient effects. Rare reports of allergic reactions including anaphylaxis.
The same on every page it applies to. Read it here; it is not repeated research.
- Immunostimulant — caution with autoimmune disease and with immunosuppressants, including after a transplant. Stimulating an immune system that is already attacking you is the wrong direction, and 'natural' does not change that.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Andrographis in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Andrographis
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | White cells and their differential — the actual immune measurement |
| Vitamin D (25-Hydroxy) | The deficiency with the most credible immune evidence |
| Zinc, Plasma | Real deficiency impairs immune function; excess doesn't help |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney, since 'detox' is what those two organs do |
The Frequent Illness & Immune Resilience panel covers these in one order — 8 markers, $97.65 with the discount applied.
Check results you already have → · All 103 markers A–Z
Andrographis — frequently asked questions
What is Andrographis?
An immune herb with strong evidence for shortening colds and respiratory infections — sometimes called 'Indian echinacea.'
What is the suggested dose of Andrographis?
As directed at first symptoms (standardized andrographolides). This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Andrographis dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Andrographis?
Coach Cam sources Andrographis from vetted, top-rated brands on iHerb — use the buy link on this page.
Andrographis inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Andrographis is used for
Andrographis appears under 1 goal in the goal router.
Related Immune & Detox supplements
Where this goes next
Andrographis is the acute arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.